

TOWNSEND and TOWNSEND and CREW LLP

By: Timothy S. Parker  
Timothy S. Parker

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Steven W. Dow, et al.

Application No.: 10/621,254

Filed: July 14, 2003

For: VACCINES USING PATTERN  
RECOGNITION RECEPTOR-  
LIGAND:LIPID COMPLEXES

Customer No. 20350

Confirmation No.: 9736

Examiner: HOLLERAN, Anne L.

Art Unit: 1643

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER  
37 CFR §1.97 and §1.98

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08B are being called to the attention of the Examiner. Copies of the references in compliance with the requirements of 37 CFR §1.98(a)(2) are enclosed.

Also enclosed is a copy of an International Search Report dated March 6, 2007, which was issued in corresponding PCT application no. PCT/US04/18363, and in which these references were cited.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ALH/

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

CERTIFICATION

I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

*Karen Babyak-Dow*  
Karen B. Dow  
Reg. No. 29,684

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 858-350-6100  
Fax: 415-576-0300  
KBD:tsp

61066650 v1

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<i>Application Number</i>	10/621,254
		<i>Filing Date</i>	July 14, 2003
		<i>First Named Inventor</i>	Dow, Steven W.
		<i>Art Unit</i>	1643
		<i>Examiner Name</i>	HOLLERAN, Anne L.
		<i>Attorney Docket Number</i>	021819-000300US
Sheet	1	of	1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BA	ISHII, Ken J., et al. "Toll' Gates for Future Immunotherapy", <i>Current Pharmaceutical Design</i> , 2006) 12:4135-4142	
	BB	LASKER, Michael V., et al. "Intracellular TLR Signaling: A Structural Perspective on Human Disease", <i>Immunol.</i> (2006) 177(1):11-16	<input type="checkbox"/>
	BC	MIGGIN, Sinead M., et al. "New insights into the regulation of TLR signaling", <i>Journal of Leukocyte Biology</i> (2006) 80(2):220-226	<input type="checkbox"/>
	BD		<input type="checkbox"/>
	BE		<input type="checkbox"/>
	BF		<input type="checkbox"/>
	BG		<input type="checkbox"/>
	BH		<input type="checkbox"/>
	BI		<input type="checkbox"/>
	BJ		<input type="checkbox"/>

Examiner Signature	ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ALH/ (02/23/2008)	
	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.